Articles avec mandats d'accès public - Shahneen SandhuEn savoir plus
Non disponibles : 22
Vérifier
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ...
The Lancet Oncology 19 (5), 672-681, 2018
Exigences : National Health and Medical Research Council, Australia
Vérifier
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
Exigences : National Health and Medical Research Council, Australia
Vérifier
The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
SK Sandhu, WR Schelman, G Wilding, V Moreno, RD Baird, S Miranda, ...
The lancet oncology 14 (9), 882-892, 2013
Exigences : US National Institutes of Health, Cancer Research UK, Prostate Cancer UK
Vérifier
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ...
The Lancet 398 (10295), 131-142, 2021
Exigences : Government of Spain
Vérifier
Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu …
SP Thang, J Violet, S Sandhu, A Iravani, T Akhurst, G Kong, AR Kumar, ...
European urology oncology 2 (6), 670-676, 2019
Exigences : National Health and Medical Research Council, Australia, Ministry of Health …
Vérifier
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
MD Forster, KJ Dedes, S Sandhu, S Frentzas, R Kristeleit, A Ashworth, ...
Nature reviews Clinical oncology 8 (5), 302-306, 2011
Exigences : Fonds national suisse, Cancer Research UK
Vérifier
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
A Omlin, C Pezaro, D Mukherji, AM Cassidy, S Sandhu, D Bianchini, ...
European urology 64 (2), 300-306, 2013
Exigences : Cancer Research UK, Prostate Cancer UK
Vérifier
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
D Lorente, J Mateo, Z Zafeiriou, AD Smith, S Sandhu, R Ferraldeschi, ...
Nature reviews urology 12 (1), 37-47, 2015
Exigences : Cancer Research UK, UK Medical Research Council, Prostate Cancer UK
Vérifier
Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors
JH Lee, AM Menzies, MS Carlino, AC McEvoy, S Sandhu, AM Weppler, ...
Clinical Cancer Research 26 (15), 4064-4071, 2020
Exigences : National Health and Medical Research Council, Australia
Vérifier
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
A Iravani, MM Osman, AM Weppler, R Wallace, A Galligan, A Lasocki, ...
European journal of nuclear medicine and molecular imaging 47, 2776-2786, 2020
Exigences : National Health and Medical Research Council, Australia
Vérifier
PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer
B Basu, SK Sandhu, JS De Bono
Drugs 72, 1579-1590, 2012
Exigences : Cancer Research UK
Vérifier
Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy
CJ Sweeney, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
European Urology 80 (3), 275-279, 2021
Exigences : National Health and Medical Research Council, Australia, Canadian Cancer Society
Vérifier
Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy
N Dhiantravan, J Violet, R Eapen, O Alghazo, M Scalzo, P Jackson, ...
European urology focus 7 (2), 234-237, 2021
Exigences : Medical Research Future Fund, Australia
Vérifier
The emerging role of poly (ADP-Ribose) polymerase inhibitors in cancer treatment
S K. Sandhu, T A. Yap, J S. de Bono
Current drug targets 12 (14), 2034-2044, 2011
Exigences : Cancer Research UK
Vérifier
γδ T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival
NA Gherardin, K Waldeck, A Caneborg, LG Martelotto, S Balachander, ...
Cancer immunology research 9 (6), 612-623, 2021
Exigences : Australian Research Council, National Health and Medical Research Council …
Vérifier
ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration …
L Emmett, S Subramaniam, AM Joshua, M Crumbaker, A Martin, ...
BJU international 128 (5), 642-651, 2021
Exigences : National Health and Medical Research Council, Australia, Medical Research …
Vérifier
18F-fluorodeoxyglucose positron emission tomography/computed tomography for assessing tumor response to immunotherapy in solid tumors: melanoma and beyond
RJ Hicks, A Iravani, S Sandhu
PET clinics 15 (1), 11-22, 2020
Exigences : National Health and Medical Research Council, Australia
Vérifier
Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series
A Iravani, C Mitchell, T Akhurst, S Sandhu, MS Hofman, RJ Hicks
Clinical Genitourinary Cancer 19 (4), e200-e205, 2021
Exigences : National Health and Medical Research Council, Australia
Vérifier
Novel endoscopic scoring system for immune mediated colitis: A Multicenter Retrospective Study of 674 Patients
Y Wang, H Abu-Sbeih, T Tang, M Shatila, D Faleck, J Harris, M Dougan, ...
Gastrointestinal Endoscopy, 2024
Exigences : National Institute for Health Research, UK, Wellcome Trust, AIRC Foundation …
Vérifier
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu] Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant …
A Gafita, AJ Martin, L Emmett, M Eiber, A Iravani, WP Fendler, J Buteau, ...
European Urology Oncology, 2024
Exigences : National Health and Medical Research Council, Australia
Les informations concernant la publication et le financement sont déterminées automatiquement par un programme informatique